MedTrace Logo

Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease

NCT03623932 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-03-23

No results posted yet for this study

Summary

Evaluation of hypnosis therapy efficacy in addition to pharmacologic standard treatment of Croh disease during remission by the evaluation of quality of life;

Conditions

  • Crohn Disease

Interventions

DRUG

immunosuppressor/TNFalpha

Standard Treatment : immunosuppressor/TNFalpha as in standard practice

BEHAVIORAL

Hypnosis

8 hypnosis group sessions during 2 months

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-13
Primary Completion
2021-11-12
Completion
2021-11-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03623932 on ClinicalTrials.gov